Neuroplastic Alterations of the Motor Cortex by Caffeine

Status Completed

Clinical Trial Summary

Caffeine is a psychostimulant drug. It acts as a competitive antagonist at adenosine receptors, which modulate cortical excitability as well. In deep brain stimulation (DBS), the production of adenosine following the release of adenosine triphosphate (ATP) explains the reduction of tremor. Binding of adenosine to adenosine A1 receptors suppresses excitatory transmission in the thalamus and hereby reduces both tremor-and DBS-induced side effects. Also, the effect of adenosine was attenuated following the administration of the 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) adenosine A1 receptor antagonist. Therefore, the presence of a receptor antagonist such as caffeine was suggested to reduce the effectiveness of deep brain stimulation (DBS) in treating tremor and other movement disorders.

Based on this finding, the investigators hypothesize that the antagonistic effect of caffeine can tentatively block the excitatory effects of transcranial alternating current stimulation (tACS). The plasticity effects might differ among caffeine users and non- caffeine users depending on the availability of receptor binding sites.

Apart from that, a major issue in NIBS studies including those studying motor-evoked potentials is the response variability both within and between individuals. The trial to trial variability of motor evoked potentials (MEPs) may be affected by many factors. Inherent to caffeine is its effect on vigilance. In this study, the investigator shall monitor the participant's vigilance by pupillometry to (1) better understand the factors, which might cause variability in transcranial excitability induction studies and (2) to separate the direct pharmacological effect from the indirect attentional effect of caffeine.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04011670
Study type	Interventional
Source	University Medical Center Goettingen
Contact
Status	Completed
Phase	N/A
Start date	July 15, 2019
Completion date	November 19, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06038903` - The Turkish Version Of The Brief-Caffeine Expectancy Questionnaire
Completed	`NCT02900261` - Study on Sodium and Caffeine in Children and Adolescents
Completed	`NCT03850275` - The Effects of e+Shots Energy Beverage on Mental Energy	N/A
Completed	`NCT01924481` - Effects of a Cocoa Shot on the Human Brain	N/A
Completed	`NCT01330680` - Genetic Determinants of Cardiovascular Response to Coffee Drinking	N/A
Completed	`NCT00184912` - The Effect of Caffeine on Ischemic Preconditioning	N/A
Completed	`NCT03859882` - Protocol PERCAF 2018	N/A
Completed	`NCT02832401` - The Impact of Caffeine on Cognition in Schizophrenia	N/A
Completed	`NCT04560595` - Remote Guided Caffeine Reduction	N/A
Recruiting	`NCT05503732` - Effects of Energy Drinks on Sleep and Cardiovascular Health	N/A
Not yet recruiting	`NCT05521386` - The Effects of Caffeine on Heart Rate and Heart Rate Variability	N/A
Completed	`NCT06039358` - Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects	N/A
Active, not recruiting	`NCT04547868` - Can Coffee/Caffeine Improve Post-Operative Gastrointestinal Recovery	N/A
Completed	`NCT05559372` - Energy Drink Effects on Performance, Mood, and Cardiovascular Outcomes	N/A
Completed	`NCT01783561` - Early Versus Routine Caffeine Administration in Extremely Preterm Neonates	Phase 4
Completed	`NCT04852315` - Acute Caffeine Ingestion on Futsal Performance	N/A
Completed	`NCT05975489` - Genetics in the Effect of Caffeine on Fat Oxidation	N/A
Recruiting	`NCT03298347` - Caffeine for Preterm Infants With Apnea of Prematurity(AOP)	N/A
Completed	`NCT01435486` - Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants	N/A
Completed	`NCT04869176` - Effect of Caffeine on Heart Rate Variability in Newborns	N/A